The JV Company is expected to become operational in Q2 of FY’25, the company stated.
Dr. Reddy’s Laboratories Inc. has not received any reports of adverse events related to this recall to date, it stated.
DailyBloom IBS care plan aims to bridge the gap in the effective management of IBS by providing patients in India…
In 2023, Dr. Reddy’s launched Nerivio in India. In India, Nerivio is supported by Dr. Reddy’s unique patient support programme…
Heart failure is a major public health issue affecting more than 8-10 million people in India.
Integrating AI and ML-based solutions with Aurigene’s core capabilities in chemical design, synthesis, and assessment in bioassays will facilitate faster…
On plans to explore new disease areas, Ramana said that they are looking at both acquisitions and in-licensing deals of…
Dr Reddy’s Laboratories posted revenue from operations at Rs 7236.80 crore, up 6.6 per cent as against Rs 6789.80 crore…
MenoLabs portfolio of products is sold in the United States, primarily through the brand’s own and other e-commerce marketplaces including…
Satish Reddy, the dynamic chairman of Dr. Reddy’s Laboratories, stands as a testament to the prowess of the second generation…
The agreement also includes development and regulatory milestones up to USD 40 million should all such development and regulatory milestones…
In terms of our expectations for the Indian market, India market continues to be the focus market, M. V. Ramana,…
Dr Reddy’s Laboratories posted revenue from operations at Rs 6902.60 crore, up 9 per cent as against Rs 6331.80 crore…
According to the Indian Council of Medical Research – India Diabetes (ICMR-INDIAB) national cross-sectional study, it is estimated that India…
Prabhudas Lilladher’s report recommended investors to buy the Dr Reddy’s Laboratories shares with a target price of Rs 6,000, 9.25%…
It is the generic version of KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food…
Meanwhile, the North America made for 47% of the total sales for Dr Reddy’s in the quarter, while 17% each…
Dr Reddy’s also reported healthy revenue growth of 29 per cent YoY to Rs 6,738.4 crore from Rs 5,215.40 crore…